Joseph Group Capital Management Has $1.02 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Joseph Group Capital Management grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 20.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,045 shares of the company’s stock after buying an additional 520 shares during the quarter. Joseph Group Capital Management’s holdings in Medpace were worth $1,016,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Thrivent Financial for Lutherans lifted its position in Medpace by 61.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 14,430 shares of the company’s stock worth $4,817,000 after buying an additional 5,484 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Medpace by 1.9% in the third quarter. Mutual of America Capital Management LLC now owns 13,738 shares of the company’s stock worth $4,586,000 after acquiring an additional 255 shares during the last quarter. Natixis Advisors LLC bought a new stake in shares of Medpace during the third quarter valued at approximately $3,754,000. Sheaff Brock Investment Advisors LLC grew its stake in shares of Medpace by 0.8% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 5,476 shares of the company’s stock valued at $1,828,000 after purchasing an additional 41 shares during the last quarter. Finally, Schulhoff & Co. Inc. increased its holdings in shares of Medpace by 11.6% in the third quarter. Schulhoff & Co. Inc. now owns 2,600 shares of the company’s stock valued at $868,000 after purchasing an additional 270 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

Shares of MEDP opened at $308.93 on Tuesday. The firm has a market capitalization of $9.60 billion, a PE ratio of 27.05, a P/E/G ratio of 1.72 and a beta of 1.37. The stock has a 50 day simple moving average of $341.51 and a 200 day simple moving average of $375.46. Medpace Holdings, Inc. has a 52-week low of $268.80 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the business posted $2.22 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft lowered their target price on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. Guggenheim lowered their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and dropped their price target for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and a consensus target price of $380.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.